JOSÉ ÁNGEL
GARCÍA SÁENZ
Profesor asociado de Ciencias de la Salud
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (13)
2023
-
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
Breast, Vol. 67, pp. 94-101
-
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400
2022
-
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
Cancers, Vol. 14, Núm. 19
-
Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study
European Journal of Clinical Nutrition, Vol. 76, Núm. 9, pp. 1343-1346
2021
-
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL
Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499
-
Trajectories of alcohol consumption during life and the risk of developing breast cancer
British Journal of Cancer, Vol. 125, Núm. 8, pp. 1168-1176
2020
-
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
Annals of Oncology, Vol. 31, Núm. 9, pp. 1223-1230
-
Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study
Scientific Reports, Vol. 10, Núm. 1
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
2019
2012
2010
-
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
Breast Cancer Research and Treatment, Vol. 122, Núm. 1, pp. 169-176
2003
-
Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: A Cooperative Study by the GEICAM Group
Clinical Breast Cancer, Vol. 3, Núm. 6, pp. 399-404